California's Stem Cell Agency
California Institute for Regenerative Medicine
Our preclinical data provide compelling support that anti-CD47 antibody might be a treatment strategy for many different cancer types, including breast, bladder, colon, ovarian, glioblastoma, leiomyosarcoma, squamous cell carcinoma, multiple myeloma, lymphoma, and acute myelogenous leukemia. Development of specific therapies that target all cancer stem cells is necessary to achieve improved outcomes, especially for sufferers of metastatic disease.
www.cirm.ca.gov/our-progress/awards/clinical-investigation-humanized-anti-cd47-antibody-targeting-cancer-stem-cells
stemcell.stanford.edu/CD47/ 
